TNF and rheumatoid arthritis: In the ORAL surveillance study, a safety, non-inferiority trial mandated by the Food and Drug Administration (FDA), patients with RA aged ≥50 years who had at least 1 CV risk factor were randomized to tofacitinib or to a TNF inhibitor.